Apparently upwards of 70% of type 2 diabetics have NAFLD. Of those type 2 diabetics with NAFLD, about half have NASH and 1/3 have significant liver fibrosis: https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/fatty-liver-disease-an-underdiagnosed-complication-of-type-2-diabetes

Thanks for the great post Jonzobot!

For the scientific DD junkies out there: my DD file didn't come up with much for "apabetalone for Non-alcoholic fatty liver disease" except I did find the following on Non-alcoholic Steatohepatitis (NASH) which is "affiliated" with NFLD.

NASH (Non-alcoholic Steatohepatitis)

https://www.nature.com/articles/s41598-018-35653-4

https://www.nature.com/articles/d41573-019-00086-9

Nlrp3 and the inflamasome activation (Parkinsons, Alzheimers, gout)

"NLRP3 has also been linked via preclinical data with nearly two dozen other conditions — including atherosclerosis, Alzheimer disease, gout, Parkinson disease, rheumatoid arthritis and non-alcoholic steatohepatitis (NASH).  

“All the big pharma companies want to block this target. It ticks all the boxes,” says O’Neill.""

BTW, ladies and gentlemen....Apabetalone down-regulates NLRP3.

https://www.investors.com/news/technology/nash-liver-disease-treatment-biotech-companies-billions-sales/

https://www.cnbc.com/2018/12/21/the-35-billion-race-for-a-cure-for-a-liver-disease-that-affects-millions.html

https://www.fiercebiotech.com/biotech/acquisitive-allergan-buys-micro-cap-nash-biotech-tobira-months-after-trial-miss